Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Applied Genetic Technologies Corp.
  • Argos Therapeutics Inc.
  • Can-Fite BioPharma Ltd.
  • Celator Pharmaceuticals Inc.
  • Celldex Therapeutics Inc.
  • Concert Pharmaceuticals
  • CTI BioPharma
  • Cytori Therapeutics Inc.
  • DelMar Pharmaceuticals Inc.
  • Dendreon Corp.
  • Flex Pharma
  • Galena Biopharma Inc.
  • GenVec Inc.
  • ImmunoCellular Therapeutics Ltd.
  • Isis Pharmaceuticals Inc.
  • Lion Biotechnologies
  • MEI Pharma Inc.
  • OncoSec Medical Inc.
  • Oncothyreon Inc.
  • Paratek Pharmaceuticals Inc.
  • Peregrine Pharmaceuticals Inc.
  • Rexahn Pharmaceuticals Inc.
  • ROTH Capital Partners
  • Stemline Therapeutics Inc.
  • Sunesis Pharmaceuticals Inc.
  • Synta Pharmaceuticals Corp.
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics Inc.
  • Threshold Pharmaceuticals Inc.
  • Verastem Inc.
  • Vericel Corp.
  • Viralytics Ltd.
  • Zosano Pharma Corp.
  • ZZ-OLD Lion Biotechnologies Inc.

Joseph Pantginis

ROTH Capital Partners

Image: Joseph Pantginis

Joseph Pantginis, Ph.D., joined ROTH Capital Partners in 2009. Prior to joining ROTH, Pantginis was a senior biotech analyst at Merriman Curhan Ford (now Merriman Holdings Inc.). Pantginis was also a senior biotechnology analyst at Canaccord Adams, focusing on the oncology, inflammation and infectious disease spaces. Prior to Canaccord Adams he was a biotech analyst at several firms, including JbHanauer & Co., First Albany Corp., Commerce Capital Markets Inc. and Ladenburg Thalmann & Co. Inc. Prior to his tenure on Wall Street, Pantginis served as an associate manager/scientist of Regeneron Pharmaceuticals' Retrovirus Core Facility. Pantginis received a master's degree in business administration (finance) from Pace University; a doctorate in molecular genetics and a master's degree from Albert Einstein College of Medicine; and a bachelor's degree from Fordham University.




Recent Interviews

A Bull Run Hiccup: 2015 Small-Cap Biotech Watchlist Update (5/13/15) It's been four months since The Life Sciences Report's 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase in San Francisco. The year is off to a bumpy start, though the rough ride is not predicated, necessarily, on individual company performance. Read on for highlights of the Watchlist's Q1/15 performance.

Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry (1/29/15) For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015.

The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here? (1/27/15) At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue into 2015 and beyond. The experts also sent investors who attended the panel discussion of The Life Sciences Report's 2015 Small-Cap Biotech Watchlist home with a bundle of robust investment opportunities, including a few new names. Read on to see which companies made the list, and why.

Recent Quotes

"SNSS is targeting its formal meeting with the FDA in mid-2015 and, if successful, a rolling NDA submission in H2/15." (5/13/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report 2015 Small-Cap Biotech Watchlist Update with Joe Pantginis More >

"We believe the RNN story is prepped for success." (5/11/15) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"The induction CR/CRi rate later in Q2/15 is a major catalyst for CPXX." (5/7/15) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"SNSS targets meeting with the FDA and the EMA in mid-2015." (5/5/15) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"Important background activities continue at SNSS." (4/27/15) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CANF announced it will resume its psoriasis program for CF101." (4/27/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"CANF's agreement with Cipher validates the commitment to CF101." (3/23/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"CANF completed development of the commercial biomarker test for A3AR." (3/18/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

more comments

"RNN's Phase 1 Supinoxin and RX-3117 studies wrap up around mid-2015." (3/17/15) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"This year should be a turning point for IMUC, so we reiterate our Buy rating." (3/13/15) ImmunoCellular Therapeutics Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"We see upside for SNSS shares in 2015." (3/13/15) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We believe 2015 will see a flurry of activity out of DMPI." (2/18/15) DelMar Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CANF's Phase 2/3 study of CF101 in plaque psoriasis patients is complete; we believe now is a good time to buy." (2/4/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"We have high confidence in CPXX's CPX-351, which meets a continuing unmet medical need." (1/20/15) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"SNSS shares should perform well in 2015." (12/15/14) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We reiterate our Buy rating for CPXX." (12/8/14) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"DMPI has a valuable, novel asset with distinguishing attributes." (11/17/14) DelMar Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"65% of the target group for IMUC's ICT-107 Phase 2 trial are alive compared to 50% in the control group." (11/14/14) ImmunoCellular Therapeutics Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"In Q3/14, SNSS reported EPS of $0.25, beating our estimate and the consensus." (11/11/14) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"The FDA gave orphan status to RNN's RX-3117 for pancreatic cancer." (9/24/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We see significant partnering potential for CANF's rheumatoid arthritis drug." (9/2/14) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"The RNN story can now be viewed as a ground floor opportunity." (8/14/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"The RNN story can now be viewed as an emerging opportunity." (7/18/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"RNN's RX-3117 has potential to be a sleeper product candidate." (6/5/14) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

"We initiate coverage on RNN with a Buy rating." (1/9/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"Japan's new Regenerative Medicine Law is positive for CYTX." (11/21/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

"We are encouraged by CYTR's preliminary response data for the first-line sarcoma study." (9/30/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX is a leading regenerative medicine player." (9/20/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX is poised for significant cash flow and its cardiovascular pipeline holds promise." (9/10/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We maintain our Buy rating on CYTR; investors should own shares." (8/6/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"We believe that IMUC is well positioned to become a leading player in the cancer immunotherapy space." (7/30/13) ImmunoCellular Therapeutics Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"We reiterate our Buy rating on CYTR." (6/24/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"We reinstate our Buy rating on CYTR." (5/31/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

fewer comments


Due to permission requirements, not all quotes are shown.